Clinical Trials Directory

Trials / Completed

CompletedNCT07135154

Postoperative Opioid Consumption in Gastric Sleeve Surgery

Comparison of Balanced Anesthesia Protocols in Gastric Sleeve Surgery in Terms of Postoperative Opioid Consumption

Status
Completed
Phase
Study type
Observational
Enrollment
96 (actual)
Sponsor
Balikesir University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The study aimed to compare balanced anesthesia protocols using only opioids as analgesics during induction in gastric sleeve surgery with protocols using opioids and ketamine together in terms of anesthesia management, opioid side effects, and postoperative analgesia.

Detailed description

During gastric sleeve surgery under general anesthesia, various drugs are administered intraoperatively to induce loss of consciousness, immobility, and pain relief (analgesia). Opioids are the most commonly used analgesics. However, the response to opioids varies widely, and their use is associated with significant side effects. In balanced general anesthesia, in addition to opioid medications, hypnotics, NMDA antagonists (ketamine, magnesium sulfate), sodium channel blockers (local anesthetics), anti-inflammatory drugs (NSAIDs, dexamethasone), and alpha-2 agonists (dexmedetomidine, clonidine) may be used. One of the components of ERAS (Enhanced Recovery After Surgery) protocols, which aim to reduce metabolic stress developing in response to surgery and promote rapid recovery after surgery, is to provide effective postoperative analgesia while using opioids as little as possible. These different anesthesia approaches may offer options for surgery. The addition of ketamine to anesthesia induction and maintenance may affect postoperative opioid consumption. Adding ketamine to anesthesia induction and maintenance may affect postoperative opioid consumption. Reducing opioid consumption can prevent opioid-related side effects such as nausea, constipation, and itching. Opioid-related side effects such as nausea, constipation, and itching can be prevented by reducing opioid consumption.

Conditions

Timeline

Start date
2024-06-03
Primary completion
2025-03-29
Completion
2026-02-27
First posted
2025-08-21
Last updated
2026-04-14
Results posted
2026-04-14

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT07135154. Inclusion in this directory is not an endorsement.